Illumina, Inc. vs Yum! Brands, Inc. — how do they compare? Illumina, Inc. trades at $189.99 (market cap $27.94B), while Yum! Brands, Inc. trades at $145.69 (market cap $40.62B). The key difference: Yum! Brands, Inc. is the larger of the two by market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | YUM | |
|---|---|---|
Market Cap | $27.94B | $40.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $168.16 |
52-Week Low | $91.00 | $138.21 |
Enterprise Value | $29.33B | $51.88B |
Dividend Yield | — | 2.04% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
YUM trades at $147.44, down 0.32% amid bearish technical signals and negative news flow from a Taco Bell lettuce contamination outbreak. Fundamentally, the company shows revenue growth to $8.21B in 2025 with strong net income margins of 20.48%, though valuation ratios like P/E of 23.86 appear elevated. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing estimates.
The stock faces near-term headwinds from the food safety crisis but maintains analyst support with a $177 consensus target representing 20% upside. Long-term growth prospects remain intact with digital expansion and brand strength, though high debt levels and competitive pressures present ongoing risks for investors.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →